Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study
Version 2 2024-06-04, 12:35Version 2 2024-06-04, 12:35
Version 1 2018-10-01, 00:00Version 1 2018-10-01, 00:00
journal contribution
posted on 2024-06-04, 12:35authored byClara K Chow, Chinthanie Ramasundarahettige, Weihong Hu, Khalid F AlHabib, Alvaro Avezum, Xiaoru Cheng, Jephat Chifamba, Gilles Dagenais, Antonio Dans, Bonaventure A Egbujie, Rajeev Gupta, Romaina Iqbal, Noorhassim Ismail, Mirac V Keskinler, Rasha Khatib, Lanthe Kruger, Rajesh Kumar, Fernando Lanas, Scott Lear, Patricio Lopez-Jaramillo, Martin McKee, Noushin Mohammadifard, Viswanathan Mohan, Prem Mony, Andres Orlandini, Annika Rosengren, Krishnapillai Vijayakumar, Li Wei, Karen Yeates, Khalid Yusoff, Rita Yusuf, Afzalhussein Yusufali, Katarzyna Zatonska, Yihong Zhou, Shariful Islam, Daniel Corsi, Sumathy Rangarajan, Koon Teo, Hertzel C Gerstein, Salim Yusuf
Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study